December 9, 2020 08:02 AM ESTUpdated December 17, 06:54 AM

With plans to bring surufatinib stateside, Chi-Med vastly scales up manufacturing with new Chinese plant

Conner Mitchell

Hutchison China MediTech, or Chi-Med, is attempting to break new ground by bringing its internally developed oncology candidate surufatinib to US shores—which would make it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With plans to bring surufatinib stateside, Chi-Med vastly scales up manufacturing with new Chinese plant

Conner Mitchell

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

With plans to bring su­r­u­fa­tinib state­side, Chi-Med vast­ly scales up man­u­fac­tur­ing with new Chi­nese plant

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With plans to bring surufatinib stateside, Chi-Med vastly scales up manufacturing with new Chinese plant